Topic
The latest Pharmatech news and analysis from Tech Arcade.
Swiss biotech Nouscom raised €120M ($135M) on Oct 19, 2026 for a pivotal trial of NOUS-209, an off-the-shelf vaccine to prevent cancer in Lynch syndrome carriers.
The FDA approved Opus Genetics' RYZUMVI eye drop for presbyopia on Oct 16, 2026 — the fifth such drop, in a market where the first four barely sold.
Teva's WELTRUZA, the first once-monthly subcutaneous olanzapine shot, won FDA approval with zero post-injection syndrome cases in trials.
Adicet's off-the-shelf CAR-T put 54% of a small lupus trial into remission on a single dose. Then the stock dropped 22%.
The FDA approved Ultragenyx's Fayuvi, the first-ever treatment for Sanfilippo syndrome type A, a fatal childhood brain disease with zero prior options. The one-time gene therapy lists at $3.95 million.
Lilly's triple-G shot retatrutide hit 30.3% weight loss in Phase 3 — surgery territory. Then the FDA filing slipped to Q1 2027 over manufacturing.
Vera Therapeutics just won FDA accelerated approval for TRUTAKNA, the first dual BAFF/APRIL inhibitor for IgA nephropathy — priced at $425,000 a year. Here's why the two-target bet matters.
